Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid
Bristol-Myers Squibb (NYSE: BMY) is granting Dr. Reddy's Laboratories (NYSE: RDY) a volume-limited license to produce a generic version of its blockbuster multiple myeloma drug, Revlimid, beginning in 2022.
Previously, Bristol-Myers filed a patent-infringement lawsuit against Dr. Reddy's in an attempt to prevent the healthcare company from launching its generic version of Revlimid. In the second quarter, Revlimid produced $2.9 billion in revenue for Bristol-Myers.
IMAGE SOURCE: GETTY IMAGES.
Source Fool.com